Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

NCT04662710 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

895

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Gastroesophageal Adenocarcinoma

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Lenvatinib
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: Leucovorin (or Levoleucovorin)
DRUG: 5-FU

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]